Hydroxycarbamide Market

Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.

Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.

Hydroxycarbamide Market contains market size and forecasts of Hydroxycarbamide in global, including the following market information:

Global Hydroxycarbamide Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Hydroxycarbamide Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Hydroxycarbamide companies in 2021 (%)

The global Hydroxycarbamide market was valued at 239.7 million in 2021 and is projected to reach US$ 345.5 million by 2028, at a CAGR of 5.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Capsule Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hydroxycarbamide include Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech and Par Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Hydroxycarbamide manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hydroxycarbamide Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Hydroxycarbamide Market Segment Percentages, by Type, 2021 (%)

Capsule

Tablet

Global Hydroxycarbamide Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Hydroxycarbamide Market Segment Percentages, by Application, 2021 (%)

Sickle Cell Disease

Cancer

Others

Global Hydroxycarbamide Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Hydroxycarbamide Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hydroxycarbamide revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Hydroxycarbamide revenues share in global market, 2021 (%)

Key companies Hydroxycarbamide sales in global market, 2017-2022 (Estimated), (M Units)

Key companies Hydroxycarbamide sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol Myers Squibb

Taj Pharma

Beijing Jialin Pharma

Qilu Pharmaceutical

Teva Pharma

Cipla

Zydus Cadila

United Biotech

Par Pharma

Khandelwal Laboratories

Alkem (Cytomed)

Samarth Pharma

VHB Life Sciences